Differential indication of anti-craving compounds in the treatment of alcoholism;Zur differenziellen indikationsstellung von anti-craving-substanzen bei alkoholabhängigkeit

Nervenheilkunde

Volumn 23, Issue 9, 2004, Pages 521-526

  Kiefer, Falk ^a   Wiedemann, K ^a  

^a UNIVERSITY MEDICAL CENTER HAMBURG EPPENDORF   (Germany)

Author keywords

Acamprosate; Alcoholism; Anti craving; Naltrexone; Relapse prevention

Indexed keywords

ACAMPROSATE; ALCOHOL; NALTREXONE;

ALCOHOLISM; ANXIETY; DEPRESSION; DIFFERENTIAL DIAGNOSIS; DRUG EFFECT; DRUG EFFICACY; DRUG INDICATION; FUTUROLOGY; HUMAN; NEUROBIOLOGY; PHARMACOGENETICS; PRACTICE GUIDELINE; PREDICTION; PROSPECTIVE STUDY; RELAPSE; REVIEW; SOMATIC DISTRESS; SYMPTOMATOLOGY; TREATMENT OUTCOME; WITHDRAWAL SYNDROME;

EID: 9644275380     PISSN: 07221541     EISSN: None     Source Type: Journal    
DOI: 10.1055/s-0038-1626417     Document Type: Review

References (26)

1. Kiefer F, Wiedemann K. Aktueller Stand der pharmakotherapeutischen Rückfallprophylaxe bei Alkoholabhängigkeit mit Acamprosat und Naltrexon. Nervenheilkunde 2002; 4: 183-92.
2. Rammes G, Mahal B, Putzke J, Parsons Q Spielmanns P, Pestel E, Spanagel R, Zieglgänsberger W, Schadrack J. The anti-craving compound acamprosate acts as a weak NMDA-receptor antagonist, but modulates NMDA-receptor subunit expression similar to memantine and MK-801. Neuropharmacology 2001; 40: 749-60.
3. Mann K, Lehert P, Morgan MY. The efficacy of acamprosate in the maintenance of abstinence in alcohol-dependent individuals: results of a meta-analysis. Alcohol Clin Exp Res 2004; 28: 51-63.
4. Kranzler HR, VanKirk J. Efficacy of naltrexone and acamprosate for alcoholism treatment: a meta-analysis. Alcohol Clin Exp Res 2001; 25: 1335-41.
5. Streeton C, Whelan G. Naltrexone, a relapse prevention maintenance treatment of alcohol dependence: a meta-analysis of randomized controlled trials. Alcohol Alcohol 2001; 36 (6): 544-52.
6. Anton RF, Kranzler HR, Meyer RE. Neurobehavioral aspects of the pharmacotherapy of alcohol dependence. Clin Neurosci 1995; 3: 145-54.
7. Sass H. Results of a pooled analysis of 11 European trials comparing acamprosate and placebo on the treatment of alcohol dependence. Alcohol Alcohol 1995; 30: 484.
8. Volpicelli JR, Clay KL, Watson NT, O'Brien CP. Naltrexone in the treatment of alcoholism: predicting response to naltrexone. J Clin Psychiatry 1995; 56 (Suppl. 7): 39-44.
9. Jaffe AJ, Rounsaville B, Chang G, Schottenfeld RS, Meyer RE, O'Malley SS. Naltrexone relapse prevention and supportive therapy with alcoholics: an analysis of patient treatment matching. J Cons Clin Psychol 1996; 64: 1044-53.
10. Cloninger CR, Bohman M, Sigvardsson S. Inheritance of alcohol abuse: Cross-fostering analysis of adopted men. Arch Gen Psychiatry 1981; 38: 861-8.
11. Lesch OM, Walter H. Subtypes of alcoholism and their role in therapy. Alcohol Alcohol 1996; 31 (Suppl. 1): 63-7.
12. Johnson BA, Roache JD, Javors MA, DiClemente CC, Cloninger CR, Prihoda TJ, Bordnick PS, Ait-Daoud N, Hensler J. Ondansetron for reduction of drinking among biologically pre-disposed alcoholic patients: A randomized controlled trial. JAMA 2000; 284: 963-71.
13. Monterosso JR, Flannery BA, Pettinati HM, Oslin DW, Rukstalis, O'Brien CP, Volpicelli JR. Predicting treatment response to naltrexone: the influence of craving and family history. Am J Addict 2001; 10 (3): 258-68.
14. Kranzler HR, Armeli S, Tennen H, Blomqvist O, Oncken C, Petry N, Feinn R. Targeted naltrexone for early problem drinkers. J Clin Psychopharmacol 2003; 23 (3): 294-304.
15. Whitworth AB, Fischer F, Lesch OM, Nimmerrichter A, Oberbauer H, Platz T, Potgieter A, Walter H, Fleischhacker WW. Comparison of acamprosate and placebo in long-term treatment of alcohol dependence. Lancet 1996; 347: 1438-42.
16. Chick J, Hewlett H, Morgan MY, Ritson B. United Kingdom Multicentre Acamprosate Study (UKMAS): a 6-month prospective study of acamprosate versus placebo in preventing relapse after withdrawal from alcohol. Alcohol Alcohol 2000; 35: 176-87.
17. Lesch OM, Riegler A, Gutierrez K, Hertling I, Ramskogler K, Semler B, Zoghlami A, Benda N, Walter H. The European acamprosate trials: conclusions for research and therapy. J Biomed Sci 2001; 8: 89-95.
18. Kiefer F, Jahn H, Tarnaske T, Helwig H, Eriken P, Holzbach R, Kämpf P, Stracke R, Baehr M, Naber D, Wiedemann K. Comparing and combining naltrexone and acamprosate in relapse prevention of alcoholism: a double-blind, placebo-controlled study. Arch Gen Psychiatry 2003; 60: 92-9.
19. Kiefer F, Helwig H, Tarnaske T, Otte C, Jahn H, Wiedemann K. Pharmacological relapse prevention of alcoholism: predictors of outcome. Eur Addict Res 2004 (in press).
20. Derogatis LR, Lipman RS, Rickels K, Uhlenhuth EH, Covi L. The Hopkins Symptom Checklist (HSCL): a self-report symptom inventory. Behav Sci 1974; 19: 1-15.
21. Anton RF, Moak DH, Latham P. The Obsessive Compulsive Drinking Scale: A self-rated instrument for the quantification of thoughts about alcohol and drinking behavior. Alcohol Clin Exp Res 1995; 19: 92-9.
22. Mann K, Ackermann K: Die OCDS-G. Psychometrische Kennwerte der deutschen Version der Obsessive Compulsive Drinking Scale. Sucht 2000; 2: 90-100.
23. Kiefer F, Jahn H, Wiedemann K. Impact of gender for the pharmacological abstinence maintenance treatment of alcoholism. Eur Psychiatry 2004; 19 (Suppl 1): 47.
24. Mann K. Project PREDICT. Suchtforschungsverbund Baden-Württemberg 2004; www.bwsuchtweb.de
25. Heinz A, Lober S, Georgi A, Wrase J, Hermann D, Rey ER, Wellek S, Mann K. Reward craving and withdrawal relief craving: assessment of different motivational pathways to alcohol intake. Alcohol Alcohol 2003; 38 (1): 35-9.
26. Kiefer F, Wiedemann K. Combined therapy: What does acamprosate and naltrexone combination tell us? Alcohol and Alcoholism 2004 (in press).